Therapeutic combinations comprising ubiquitin-specific processing protease 1 (USP1) inhibitors and poly (ADP-ribose) polymerase (PARP) inhibitors

The present disclosure provides a therapeutic combination comprising (i) an ubiquitin-specific processing protease 1 (USP1) inhibitor and (ii) a poly ADP-ribose polymerase (PARP) inhibitor, or a pharmaceutically acceptable salt, hydrate, solvate, amorphous solid, or polymorph thereof, wherein the USP1 inhibitor comprises (I), (II) or (III) or a pharmaceutically acceptable salt, hydrate, solvate, amorphous solid or polymorph thereof. The disclosure is also directed to the use of such a combination to inhibit USP1 and/or PARP proteins and/or to treat conditions responsive to the inhibition of USP1 and/or PARP proteins and USP1 and/or PARP activity. Combinations of the present disclosure are particularly useful in the treatment of cancer. 本公开提供了治疗组合，所述治疗组合包含(i)泛素特异性加工蛋白酶1(USP1)抑制剂和(ii)多聚ADP-核糖聚合酶(PARP)抑制剂或其药学上可接受的盐、水合物、溶剂化物、非晶固体或多晶型物，其中所述USP1抑制剂包含(I)、(II)或(III)或其药学上可接受的盐、水合物、溶剂化物、非晶固体或多晶型物。本公开还针对所述组合抑制USP1和/或PARP蛋白和/或治疗对USP1和/或PARP蛋白和USP1和/或PARP活性的抑制起反应的病症的用途。本公开的组合尤其可用于治疗癌症。